Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 3;9:5562. doi: 10.1038/s41598-019-41724-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

DTA-1 Ab enhanced antitumor immunity. (a) Antitumor effect of DTA-1 Ab. CT26 subcutaneous tumors were established on both legs of BALB/c mice. DTA-1 Ab was once injected into the right tumor (IT; intratumoral injection) or into the peritoneal cavity (IP; intraperitoneal injection). Tumor volumes were measured at the indicated days. n.s.: not significant. Control: n = 14, IP: n = 14, IT (R): n = 7, IT (L): n = 7. P < 0.05; one-sided ANOVA with Turkey’s post-hoc test. (b) Antitumor effect of repeated injections of DTA-1 Ab. CT26 subcutaneous tumors were established on right leg of BALB/c mice. DTA-1 Ab was once injected into the tumor, into the peritoneal cavity or into the tail vein (IV; intravenous injection), and DTA-1 Ab was repeatedly injected into the peritoneal cavity every 4–5 days (IP repeat). Tumor volumes were measured at the indicated days. n = 7. P < 0.05; one-sided ANOVA with Turkey’s post-hoc test.